Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma

PURPOSE: Sorafenib is the first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), and its clinical response rate is only about 10%. In clinical practice, some HCC patients obtain favorable overall survival (OS) to the treatment of sorafenib while some patients do not demo...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Onco Targets Ther
Main Authors: Zhu, Zhenfeng, Xu, Litao, Zhuang, Liping, Ning, Zhouyu, Zhang, Chenyue, Yan, Xia, Lin, Junhua, Shen, Yehua, Wang, Peng, Meng, Zhiqiang
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2018
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6188073/
https://ncbi.nlm.nih.gov/pubmed/30349306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S173275
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki